Filing Details

Accession Number:
0001209191-19-034054
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-03 18:17:47
Reporting Period:
2019-05-30
Accepted Time:
2019-06-03 18:17:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1340652 Chemocentryx Inc. CCXI Pharmaceutical Preparations (2834) 943254365
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1491874 M. Geoffrey Parker C/O Chemocentryx, Inc.
850 Maude Avenue
Mountain View CA 94043
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-05-30 18,010 $6.00 85,014 No 4 M Direct
Common Stock Disposition 2019-05-30 12,815 $12.00 72,199 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2019-05-30 18,010 $0.00 18,010 $6.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
31,990 2009-12-11 2019-12-11 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 99,600 Indirect Geoffrey M Parker & Jill Gofen Parker Trustees of Geoffrey M Parker & Jill G Parker Revocable Trust
Common Stock 5,000 Indirect By Delaware Charter Guarantee & Trust Company, Trustee FBO Mr. Geoffrey Monroe Parker IRA
Footnotes
  1. Shares sold are associated with stock options that will expire in December 2019.
  2. Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $11.85 to $12.115 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
  3. As of May 30, 2019, and prior to this transaction, the exercised options were fully vested.
  4. Not applicable.